Cargando…

Serial ultra‐deep sequencing of circulating tumor DNA reveals the clonal evolution in non‐small cell lung cancer patients treated with anti‐PD1 immunotherapy

BACKGROUND: Immune‐therapy with anti‐PD1 inhibitors, such as pembrolizumab, is revolutionizing the treatment of non‐small cell lung cancers (NSCLC). However, identifying patients for the potential therapeutic response and predicting therapy resistance and early relapse remains a challenge. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Li, Wang, Yubo, Shi, Weiwei, Zhu, Mengxiao, Liu, Zhulin, Luo, Nuo, Zeng, Yanwu, He, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912064/ https://www.ncbi.nlm.nih.gov/pubmed/31692284 http://dx.doi.org/10.1002/cam4.2632

Ejemplares similares

Clonal Evolution Dynamics in Primary and Metastatic Lesions of Pancreatic Neuroendocrine Neoplasms
por: Tong, Zhou, et al.
Publicado: (2021)

Case Report: An “Immune-Cold” EGFR Mutant NSCLC With Strong PD-L1 Expression Shows Resistance to Chemo-Immunotherapy
por: Zhao, Qian, et al.
Publicado: (2022)

Circulating CD137(+) T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer
por: Zizzari, Ilaria Grazia, et al.
Publicado: (2022)

Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy
por: Cui, Xin, et al.
Publicado: (2020)

Clonal evolution of leukemia from G6PD studies
por: Bacharach, Tal, et al.
Publicado: (2023)

Baseline monocyte and its classical subtype may predict efficacy of PD-1/PD-L1 inhibitor in cancers
por: Shao, Yilin, et al.
Publicado: (2021)

Obesity diminishes response to PD-1-based immunotherapies in renal cancer
por: Boi, Shannon K, et al.
Publicado: (2020)

Genotyping of cerebrospinal fluid in lung cancer patients with leptomeningeal metastasis
por: Nie, Naifu, et al.
Publicado: (2022)

Harnessing neutrophil plasticity for HCC immunotherapy
por: Ramon-Gil, Erik, et al.
Publicado: (2023)

Prostasin regulates PD-L1 expression in human lung cancer cells
por: Chen, Li-Mei, et al.
Publicado: (2021)

Rejection of immunogenic tumor clones is limited by clonal fraction
por: Gejman, Ron S, et al.
Publicado: (2018)

Remodeling of the tumor microenvironment using an engineered oncolytic vaccinia virus improves PD-L1 inhibition outcomes
por: Lou, Jiaying, et al.
Publicado: (2021)

Resectable lung lesions malignancy assessment and cancer detection by ultra-deep sequencing of targeted gene mutations in plasma cell-free DNA
por: Peng, Muyun, et al.
Publicado: (2019)

Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis
por: Li, Xiao-Song, et al.
Publicado: (2020)

Serial type-specific human papillomavirus (HPV) load measurement allows differentiation between regressing cervical lesions and serial virion productive transient infections
por: Depuydt, Christophe E, et al.
Publicado: (2015)

Tryptophan metabolism and disposition in cancer biology and immunotherapy
por: Badawy, Abdulla A.-B.
Publicado: (2022)

Recurrent pleural effusion as a rare manifestation after prolonged PD1 inhibitor (camrelizumab)-based immunotherapy: A case report
por: Xie, Xiao-Hong, et al.
Publicado: (2023)

Circulating PD‐1 (+) cells may participate in immune evasion in peripheral T‐cell lymphoma and chidamide enhance antitumor activity of PD‐1 (+) cells
por: Zhang, Wei, et al.
Publicado: (2019)

Mutation analysis links angioimmunoblastic T-cell lymphoma to clonal hematopoiesis and smoking
por: Cheng, Shuhua, et al.
Publicado: (2021)

Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles
por: Orme, Jacob J, et al.
Publicado: (2020)

Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2018)

Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy
por: Pinter, Matthias, et al.
Publicado: (2017)

Risk stratification for lung adenocarcinoma on EGFR and TP53 mutation status, chemotherapy, and PD‐L1 immunotherapy
por: Wu, Chih‐Hsun, et al.
Publicado: (2019)

Risk of immune‐related pneumonitis for PD1/PD‐L1 inhibitors: Systematic review and network meta‐analysis
por: Huang, Yafang, et al.
Publicado: (2019)

Cell migration leads to spatially distinct but clonally related airway cancer precursors
por: Pipinikas, Christodoulos P, et al.
Publicado: (2014)

Clonal transcriptomics identifies mechanisms of chemoresistance and empowers rational design of combination therapies
por: Wild, Sophia A, et al.
Publicado: (2022)

Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab
por: Nahar, Kazi J, et al.
Publicado: (2020)

High number of PD‐1 positive intratumoural lymphocytes predicts survival benefit of cytokine‐induced killer cells for hepatocellular carcinoma patients
por: Chang, Boyang, et al.
Publicado: (2018)

PD-L1 expression in anogenital and oropharyngeal squamous cell carcinomas associated with different clinicopathological features, HPV status and prognosis: a meta-analysis
por: Qin, Yuan, et al.
Publicado: (2021)

T-cell response to checkpoint blockade immunotherapies: from fundamental mechanisms to treatment signatures
por: Elliot, Thomas A.E., et al.
Publicado: (2023)

Circulating Cell-Free DNA Reflects the Clonal Evolution of Breast Cancer Tumors
por: Kujala, Jouni, et al.
Publicado: (2022)

PD-L1 regulates tumorigenesis and autophagy of ovarian cancer by activating mTORC signaling
por: Gao, Hongmin, et al.
Publicado: (2019)

PD‐1/PD‐L1 inhibitors‐based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies
por: Ding, Lei, et al.
Publicado: (2021)

Circulating proteins and risk of pancreatic cancer: a case-subcohort study among Chinese adults
por: Kartsonaki, Christiana, et al.
Publicado: (2022)

Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy
por: Gao, Hannan, et al.
Publicado: (2020)

CD4(+) T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
por: Xiao, Minglu, et al.
Publicado: (2022)

Tumour-associated macrophages as a potential target to improve natural killer cell-based immunotherapies
por: Kitamura, Takanori
Publicado: (2023)

Evolving clonal nevus—case report with serial digital dermatoscopy and dermatopathology
por: Inskip, Mike, et al.
Publicado: (2015)

Inhibition of TCA cycle improves the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis
por: Liu, Nian, et al.
Publicado: (2023)

Integration of comprehensive genomic profiling, tumor mutational burden, and PD‐L1 expression to identify novel biomarkers of immunotherapy in non‐small cell lung cancer
por: Shi, Yunfei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r0o0f0c4osb02lujf32getlah6